Literature DB >> 15205269

Treatment of leprosy.

Diana N J Lockwood, Bhushan Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15205269      PMCID： PMC428501          DOI： 10.1136/bmj.328.7454.1447

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

Review 1.  Does there exist a subgroup of MB patients at greater risk of relapse after MDT?

Authors:  J Baohong
Journal:  Lepr Rev       Date:  2001-03       Impact factor: 0.537

2.  A clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up.

Authors:  Richard P Croft; Peter G Nicholls; Ewout W Steyerberg; Jan H Richardus; Steven G Withington; W Cairns S Smith
Journal:  Lepr Rev       Date:  2003-03       Impact factor: 0.537

Review 3.  Leprosy.

Authors:  Diana Lockwood
Journal:  Clin Evid       Date:  2002-12

4.  The return of thalidomide: new uses and renewed concerns--reply.

Authors:  Diana Lockwood; Anthony Bryceson
Journal:  Lepr Rev       Date:  2003-09       Impact factor: 0.537

Review 5.  The management of leprosy reversal reactions.

Authors:  W J Britton
Journal:  Lepr Rev       Date:  1998-09       Impact factor: 0.537

Review 6.  WHO Expert Committee on Leprosy.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1998

7.  Rifampicin/minocycline and ofloxacin (ROM) for single lesions--what is the evidence?

Authors:  D N Lockwood
Journal:  Lepr Rev       Date:  1997-12       Impact factor: 0.537

8.  Chemotherapy of leprosy for control programmes.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1982

9.  Relapses in multibacillary leprosy patients: effect of length of therapy.

Authors:  B K Girdhar; A Girdhar; A Kumar
Journal:  Lepr Rev       Date:  2000-06       Impact factor: 0.537

10.  Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1).

Authors:  W Cairns S Smith; Alison M Anderson; Stephen G Withington; Wim H van Brakel; Richard P Croft; Peter G Nicholls; Jan Hendrik Richardus
Journal:  BMJ       Date:  2004-05-24
View more
  6 in total

1.  Immune cellular parameters of leprosy and human immunodeficiency virus-1 co-infected subjects.

Authors:  Karina I Carvalho; Solange Maeda; Luciana Marti; Jane Yamashita; Patrick A J Haslett; Esper G Kallas
Journal:  Immunology       Date:  2008-02-12       Impact factor: 7.397

Review 2.  Climate change, human migration, and skin disease: is there a link?

Authors:  Johannes F Dayrit; Audi Sugiharto; Sarah J Coates; Don Eliseo Lucero-Prisno; Mark Denis D Davis; Louise K Andersen
Journal:  Int J Dermatol       Date:  2021-05-10       Impact factor: 3.204

3.  Leprosy treatment: Can we replace opinions with research?

Authors:  David M Scollard
Journal:  PLoS Negl Trop Dis       Date:  2020-10-08

4.  New Players in the Same Old Game: Disturbance of Group 2 Innate Lymphoid Cells in HIV-1 and Mycobacterium leprae Co-infected Patients.

Authors:  Pedro Henrique Papotto; Solange Maeda; Jane Tomimori; Marília Brasil Xavier; Luiz Vicente Rizzo; Esper Georges Kallas; Karina Inácio Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2015-09-03

5.  Leprosy Reaction in Thai Population: A 20-Year Retrospective Study.

Authors:  Poonkiat Suchonwanit; Siripich Triamchaisri; Sanchawan Wittayakornrerk; Ploysyne Rattanakaemakorn
Journal:  Dermatol Res Pract       Date:  2015-10-05

6.  World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.

Authors:  Maria Lazo-Porras; Gabriela J Prutsky; Patricia Barrionuevo; Jose Carlos Tapia; Cesar Ugarte-Gil; Oscar J Ponce; Ana Acuña-Villaorduña; Juan Pablo Domecq; Celso De la Cruz-Luque; Larry J Prokop; Germán Málaga
Journal:  BMC Infect Dis       Date:  2020-01-20       Impact factor: 3.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.